Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis

Bedaiwy, Mohamed A.; Abou‐Setta, Ahmed M; Desai, Nina; Hurd, William W.; Starks, David; El-Nashar, Sherif A.; Al-Inany, Hesham; Falcone, Tommaso

doi:10.1016/j.fertnstert.2010.11.017

Cited by 149 publications

(107 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[132][133][134] However, the impact of these meta-analyses are limited by flaws such as only examining women with breast cancer and only including trials that were not adequately powered and did not use blinding and/ or a placebo condition. 135,136 Further, results from earlier meta-analyses were inconsistent, with some showing a potential benefit of GnRH to preservation of ovarian function, [137][138][139] while other reviews have been unable to come to this conclusion. 140,141 Also, limited data are available on the long-term impact of GnRH on preservation of ovarian function, 132 though a 5-year follow-up analysis of a randomized trial showed that administration of a GnRH agonist does not significantly impact premature ovarian failure or future pregnancy rate.…”

Section: Options For Femalesmentioning

confidence: 99%

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Coccia¹,

Pappo²,

Beaupin³

et al. 2018

J Natl Compr Canc Netw

261

194

View full text Add to dashboard Cite

Section: Options For Femalesmentioning

confidence: 99%

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Coccia¹,

Pappo²,

Beaupin³

et al. 2018

J Natl Compr Canc Netw

261

194

View full text Add to dashboard Cite

“…Gonadal protection through hormonal manipulation with GnRH analogs for FP in women treated with gonadotoxic chemotherapy has demonstrated conflicting results (3,(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). Published clinical guidelines from clinical associations are variable in their recommendations regarding GnRH analogs.…”

Section: Usefulness Of Gonadotropin-releasing Hormone (Gnrh)mentioning

confidence: 99%

Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians

et al. 2017

View full text Add to dashboard Cite

Abstract. Increasing accessibility of fertility preservation (FP) options has permitted women to retain fertility following anticancer therapies. Several published guidelines have made recommendations for FP however their implementation into practice is currently unknown. In this review, we aim to provide oncology clinicians practical information about FP options for post-pubescent female cancer patients and recommendations for care delivery in order to answer preliminary questions and help triage whether FP referral is appropriate. Herein, we present a resource for oncology providers to guide them with FP discussions. Key points that are discussed in this critical review include: i) All cancer patients beginning a new plan of care should be informed of potential fertility risk. ii) If a woman requests further information on FP interventions, referral to a FP clinic should be made. iii) Given the evolving technologies in this area, patients should be informed of those which are proven and unproven, with oocyte and embryo preservation recognized as standard practice. iv) Random start (independent of menstrual cycle day) techniques are available to minimize oncologic treatment delays. v) Specific protocols for ovarian stimulation may be center-specific. vi) There is unlikely an increased cancer recurrence risk as a result of stimulation protocols in women with hormone-sensitive cancers. vii) Lastly, given the absence of consensus in the literature, routine use of GnRH analogs is not recommended for all cancer patients, however may be considered in select cases, such as high-risk women in whom definitive FP is not possible or feasible.

show abstract

“…Despite numerous attempts to synthesize the results in several meta-analyses [9][10][11][12][13][14][15][16][17][18][19][20] , the subject remains controversial. This systematic review and meta-analysis was designed to evaluate the efficacy of GnRHa in ovarian reserve protection before and during cancer chemotherapy in premenopausal women without previous diagnosis of infertility.…”

Section: Introductionmentioning

confidence: 99%

Gonadotropin‐releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta‐analysis

Senra

Roque

Talim

et al. 2017

Ultrasound in Obstet & Gyne

View full text Add to dashboard Cite

show abstract

Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis

Cited by 149 publications

References 29 publications

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians

Gonadotropin‐releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta‐analysis

Contact Info

Product

Resources

About